A Study to Evaluate Mirabegron in Pediatric Participants From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB)
- Conditions
- Pharmacokinetics of MirabegronOveractive Bladder (OAB)
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-11-24
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT04641975
- Locations
- 🇧🇪
Site BE32005, Gent, Belgium
🇫🇷Site FR33001, Marseille, France
🇰🇷Site KR82004, Yangsan-Si, Gyeongsangnamdo, Korea, Republic of
A Study to Assess the Effect of Food With Fezolinetant in Healthy Female Participants
- First Posted Date
- 2020-11-23
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT04641260
- Locations
- 🇺🇸
Parexel, Baltimore, Maryland, United States
A Study to Investigate the Effect of Mild and Moderate Hepatic Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Hepatic Function
- First Posted Date
- 2020-07-22
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT04482270
- Locations
- 🇺🇸
Clinical Research of West Florida, Inc., Clearwater, Florida, United States
🇺🇸Clinical Pharmacology of Miami, LLC, Miami, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
A Study to Investigate the Effect of Renal Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Renal Function
- First Posted Date
- 2020-07-20
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT04476849
- Locations
- 🇺🇸
National Institute of Clinical Research, Garden Grove, California, United States
🇺🇸Inland Empire Clinical Trials, LLC, Rialto, California, United States
🇺🇸Clinical Research of West Florida, Inc., Clearwater, Florida, United States
A Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ASP8062 With a Single Dose of Morphine in Recreational Opioid Using Participants
- First Posted Date
- 2020-06-26
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT04448561
- Locations
- 🇺🇸
Altasciences Clinical Kansas, Inc., Overland Park, Kansas, United States
A Study to Assess the Effect of a Single Dose of ASP8062 on the Multiple Dose Safety, Tolerability and Pharmacokinetics of Buprenorphine/Naloxone in Participants With Opioid Use Disorder
- Conditions
- Opioid Use Disorder
- Interventions
- First Posted Date
- 2020-06-25
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT04447287
- Locations
- 🇺🇸
Altasciences Clinical Kansas, Inc., Overland Park, Kansas, United States
A Study to Assess ASP0598 Otic Solution Following Topical Application in the Ear in Subjects With Chronic Tympanic Membrane Perforation (CTMP)
- Conditions
- Chronic Tympanic Membrane Perforation
- Interventions
- Other: Placebo
- First Posted Date
- 2020-03-12
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT04305184
- Locations
- 🇺🇸
Stanford Hospital, Palo Alto, California, United States
🇺🇸Breathe Clear Institute, Torrance, California, United States
🇺🇸ENT and Allergy Associates of Florida, Boca Raton, Florida, United States
A Study to Assess Bioequivalence of Fezolinetant Formulations in Healthy Female Participants
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2020-02-20
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT04277624
- Locations
- 🇺🇸
PAREXEL Early Phase Clinical Unit, Baltimore, Maryland, United States
A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem Duplication (ITD)
- Interventions
- Drug: granulocyte colony-stimulating factor (G-CSF)
- First Posted Date
- 2020-01-27
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT04240002
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
🇩🇪Site DE49004, Essen, Nordrhein-Westfalen, Germany
🇮🇹SIte IT39001, Roma, Italy
A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
- Conditions
- Locally Advanced or Metastatic Malignant Solid Tumors
- Interventions
- Drug: enfortumab vedotin
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 320
- Registration Number
- NCT04225117
- Locations
- 🇺🇸
Arizona Oncology, Tucson, Arizona, United States
🇺🇸University of California - San Francisco, San Francisco, California, United States
🇺🇸University of Colorado, Aurora, Colorado, United States